Immuno-Oncology | Specialty

Combining PARP Inhibitors + Checkpoint Inhibitors in TNBC

February 15th 2018

Sequencing in BRCA-Positive TNBC Patients

February 15th 2018

NCCN Guideline Changes for BRCA Testing in TNBC

February 15th 2018

Germline BRCA Mutations in TNBC

February 15th 2018

Histologic Subtyping in TNBC

February 15th 2018

Classification of Triple Negative Breast Cancer

February 15th 2018

Bristol-Myers Squibb Gains NKTR-214 Access in Nektar Collaboration

February 15th 2018

Bristol-Myers Squibb and Nektar Therapeutics have announced plans to jointly develop and market combinations of the CD122-biased cytokine NKTR-214 with nivolumab (Opdivo) or nivolumab plus ipilimumab (Yervoy) across for 20 indications in 9 tumor types.

Powles Sheds Light on Shifting Landscape in Kidney Cancer

February 13th 2018

Thomas Powles MBBS, MRCP, MD, discusses the findings from the CheckMate-214 trial, as well as continuing studies in immunotherapy and targeted therapy in kidney cancer.

Immunotherapy Combos on Horizon for Ovarian Cancer

February 11th 2018

Several phase III studies are exploring immunotherapy combinations with the potential to disrupt the systemic treatment paradigm for patients with ovarian cancer.

PARP Combos With Bevacizumab, Immunotherapy in Development for Ovarian Cancer Treatment

February 10th 2018

Rebecca C. Arend, MD, discussed novel combinations being investigated for the treatment of patients with ovarian cancer.

Pembrolizumab Survival Benefit Sustained in 2-Year Urothelial Cancer Data

February 10th 2018

Two-year follow-up data showed sustained improvements in overall survival with pembrolizumab over chemotherapy in pretreated patients with locally advanced or recurrent urothelial cancer.

Dr. Sonpavde on Fixed-Dose Durvalumab and Tremelimumab Study in Urothelial Carcinoma

February 10th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a phase IIIb safety study of fixed-dose durvalumab (Imfinzi) and tremelimumab in patients with advanced urothelial carcinoma.

Olaparib/Durvalumab Combo Shows Promise in mCRPC

February 9th 2018

The PARP inhibitor olaparib appeared to complement the antitumor activity of the PD-L1 inhibitor durvalumab in unselected men with metastatic castrate-resistant prostate cancer, according to findings from a phase II study presented at the 2018 Genitourinary Cancers Symposium.

Dr. Joshi Discusses Durvalumab and Radiation Therapy in Bladder Cancer

February 9th 2018

Monika Joshi, MD, assistant professor, Penn State Hershey Medical Center, discusses a phase Ib study of durvalumab (Imfinzi) and radiation therapy (DUART) followed by adjuvant durvalumab in patients with urothelial carcinoma.

The Future of Treatment in Hepatocellular Carcinoma

February 9th 2018

Locoregional Approaches in Hepatocellular Carcinoma

February 9th 2018

KEYNOTE-224: Second-Line Pembrolizumab

February 9th 2018

Immunotherapy Approaches in Hepatocellular Carcinoma

February 9th 2018

CELESTIAL Trial: Second-Line Cabozantinib's Value in HCC

February 9th 2018

REFLECT Trial: Frontline Lenvatinib's Value in HCC

February 9th 2018